Regression of established murine carcinoma metastases following vaccination with tumour-associated a
Author: ["Ofer Mandelboim","Ezra Vadai","Mati Fridkin","Anne Katz-Hillel","Michael Feldman","Gideon Berke","Lea Eisenbach"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
The cure of micrometastases following surgery is the major goal of cancer immunotherapy. We have recently isolated tumour-associated antigen (TAA) peptides, MUT 1 and MUT 2, derived from a mutated connexin 37 gap-junction protein, from the malignant 3LL-D122 murine lung carcinoma. We now report that synthetic MUT 1 or MUT 2 induces effective antitumour cytoxic T lymphocytes. Peptide vaccines protect mice from spontaneous metastases of 3LL-D122 tumours. Moreover, peptide vaccines reduce metastatic loads in mice carrying pre-established micrometastases. Tumour-specific immunity was primarily mediated by CD8+ T cells. This is the first evidence that peptide therapy may be effective in treatment of residual tumours and provides a rationale for the development of peptide vaccines as a modality for cancer therapy.
Cite this article
Mandelboim, O., Vadai, E., Fridkin, M. et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1, 1179–1183 (1995). https://doi.org/10.1038/nm1195-1179